Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab
2016
Objective: Clinical trials have shown the efficacy of adalimumab
in Crohn’s disease, but the outcome in regular practice remains
unknown. The aim of the study was to examine clinical status, quality
of life, and work productivity of Crohn’s disease patients receiving
adalimumab for one year in the context of usual clinical practice.
Material and methods: This was a prospective, observational
study with a one-year follow-up. After baseline, Crohn’s disease
patients were evaluated at 1, 3, 6, 9, and 12 months after
starting treatment with adalimumab. Outcome variables included:
clinical status (measured with CDAI), quality of life (measured with
EuroQoL-5D and IBDQ), and work productivity (measured with
WPAI questionnaire). These outcome variables were compared
using the Student’s t test or Wilcoxon test for paired comparison
data according to the data distribution. Statistical significance was
set at two-sided p < 0.05.
Results: The sample was composed of 126 patients (age
[mean] 39.1 ± [standard deviation] 13.8 years; 51% male). Significant
changes were observed during the follow-up period: CDAI
decreased from [median] 194 ([25-75 percentiles] 121-269) to 48.2
(10.1-122.0) (p < 0.05); the EuroQoL-5D increased from 0.735
(0.633-0.790) to 0.797 (0.726-1.000) (p < 0.05); the EuroQoL-
5D visual analogue scale increased from 50.0 (40-70) to 80.0 (60-
90); (p < 0.05) and the IBDQ increased from 56.7 (51.6-61.5) to
67.5 (60.1-73.6) (p < 0.05). The total work productivity impact
decreased from 53% to 24% (p < 0.05).
Conclusions: In regular practice, adalimumab is clinically
effective in the treatment of Crohn’s disease patients and results in
a significant improvement in quality of life and work productivity.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
31
References
4
Citations
NaN
KQI